文献速递白血病

解析前B细胞白血病骨髓微环境带来的新治疗机会

New therapeutic opportunities from dissecting the pre-B leukemia bone marrow microenvironment.
PubMed 文献 · Leukemia · 2018-05-08

研究在免疫健全的BCR-ABL1+小鼠模型中解析前B细胞急性淋巴细胞白血病(pre-B ALL)发生过程中骨髓微环境的变化,发现造血受扰、B淋巴生成受损、胶原产生减少、成骨细胞数量下降及严重骨丢失,白血病细胞产生高水平RANKL足以引起破骨细胞介导的骨吸收;体内给予唑来膦酸可挽救白血病所致骨丢失、降低疾病负荷并延长生存。

要点

  • 白血病发生过程中骨髓微环境出现造血受扰、B淋巴生成受损、胶原产生减少和成骨细胞数量下降。
  • 白血病小鼠出现严重骨丢失,白血病细胞产生高水平RANKL足以引起破骨细胞介导的骨吸收。
  • 体内给予唑来膦酸可挽救白血病所致骨丢失、降低疾病负荷并延长白血病小鼠生存。

核心结论

  • 靶向白血病所致骨丢失是前B细胞急性淋巴细胞白血病的一种治疗策略。

研究设计与样本

  • 研究在免疫健全的BCR-ABL1+小鼠模型中聚焦前B细胞急性淋巴细胞白血病(pre-B ALL)的发生发展。

主要发现

  • 白血病发生过程中骨髓微环境造血受扰、B淋巴生成受损、胶原产生减少、成骨细胞数量下降。
  • 白血病小鼠在白血病发生过程中出现严重骨丢失。
  • 白血病细胞产生高水平核因子κB受体活化因子配体(RANKL),足以引起破骨细胞介导的骨吸收。
  • 体内给予唑来膦酸可挽救白血病所致骨丢失、降低疾病负荷并延长白血病小鼠生存。

临床怎么用

  • 作者认为靶向白血病所致骨丢失是前B细胞急性淋巴细胞白血病的一种治疗策略。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The microenvironments of leukemia and cancer are critical for multiple stages of malignancies, and they are an attractive therapeutic target. While skeletal abnormalities are commonly seen in children with acute lymphoblastic leukemia (ALL) prior to initiating osteotoxic therapy, little is known about the alterations to the bone marrow microenvironment during leukemogenesis. Therefore, in this study, we focused on the development of precursor-B cell ALL (pre-B ALL) in an immunocompetent BCR-ABL1+ model. Here we show that hematopoiesis was perturbed, B lymphopoiesis was impaired, collagen production was reduced, and the number of osteoblastic cells was decreased in the bone marrow microenvironment. As previously found in children with ALL, the leukemia-bearing mice exhibited severe bone loss during leukemogenesis. Leukemia cells produced high levels of receptor activator of nuclear factor κB ligand (RANKL), sufficient to cause osteoclast-mediated bone resorption. In vivo administration of zoledronic acid rescued leukemia-induced bone loss, reduced disease burden and prolonged survival in leukemia-bearing mice. Taken together, we provide evidence that targeting leukemia-induced bone loss is a therapeutic strategy for pre-B ALL.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Cheung LC, Tickner J, Hughes AM, et al. New therapeutic opportunities from dissecting the pre-B leukemia bone marrow microenvironment. Leukemia. 2018. PMID: 29740160. doi:10.1038/s41375-018-0144-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。